Stock ATHA ATHIRA PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Athira Pharma, Inc.

Equities

ATHA

US04746L1044

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
1.96 USD -3.92% Intraday chart for Athira Pharma, Inc. -2.49% -19.34%
04-15 Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer CI
04-11 Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease CI

Business Summary

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.

Number of employees: 66

Managers

Managers TitleAgeSince
Mark Litton CEO
 Chief Executive Officer 56 10/07/19
Andrew Gengos DFI
 Director of Finance/CFO 59 17/05/23
Rachel Lenington COO
 Chief Operating Officer 51 13/06/21
Kevin Church CTO
 Chief Tech/Sci/R&D Officer 39 31/12/15
Julie Rathbun IRC
 Investor Relations Contact - -
Robert Renninger PRN
 Corporate Officer/Principal - 30/06/20
Samantha Willing HRO
 Human Resources Officer - 01-31
Mark Worthington LAW
 General Counsel 58 31/05/21

Members of the board

Members of the board TitleAgeSince
Grant Pickering BRD
 Director/Board Member 56 26/01/22
John Fluke BRD
 Director/Board Member 81 31/12/12
Joseph Edelman BRD
 Director/Board Member 67 30/04/20
James Johnson BRD
 Director/Board Member 67 31/07/20
Barbara Kosacz BRD
 Director/Board Member 66 07/03/21
Mark Litton CEO
 Chief Executive Officer 56 10/07/19
Michael Panzara BRD
 Director/Board Member 57 17/03/22
Kelly Romano CHM
 Chairman 62 13/12/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 38,326,652 31,772,063 ( 82.90 %) 0 82.90 %

Shareholders

NameEquities%Valuation
Perceptive Advisors LLC
14.10 %
5,402,964 14.10 % 15 M $
Baker Bros. Advisors LP
8.229 %
3,153,807 8.229 % 9 M $
Richard Kayne
5.175 %
1,983,468 5.175 % 5 M $
Vanguard Global Advisers LLC
4.432 %
1,698,453 4.432 % 5 M $
Propel Bio Management LLC
3.895 %
1,492,792 3.895 % 4 M $
Simplify Asset Management, Inc.
3.895 %
1,492,792 3.895 % 4 M $
Tang Capital Management LLC
3.008 %
1,152,715 3.008 % 3 M $
BML Capital Management LLC
2.348 %
900,000 2.348 % 2 M $
BlackRock Institutional Trust Co. NA
1.714 %
656,799 1.714 % 2 M $
Millennium Management LLC
1.189 %
455,857 1.189 % 1 M $

Company contact information

Athira Pharma, Inc.

18706 North Creek Parkway Suite 104

98011, Bothell

+

http://www.athira.com
address Athira Pharma, Inc.(ATHA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.96 USD
Average target price
7.417 USD
Spread / Average Target
+278.40%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ATHIRA PHARMA, INC. Stock Athira Pharma, Inc.
-19.34% 78.19M
MODERNA, INC. Stock Moderna, Inc.
+26.28% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.99% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.36% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.47% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.58% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.75% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.02% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ATHA Stock
  4. Company Athira Pharma, Inc.